Table 2.
Patient clinicopathological characteristics stratified by whether they received chemotherapy n (%)
| Variable | Patients (n = 106) | Chemotherapy (n = 53) | Oxaliplatin (n = 33) | Irinotecan (n = 9) | HAI (n = 11) | P value |
| Mean age, yr | 60 | 59.8 | 56.9 | 56.9 | 54.2 | 0.26 |
| Gender | ||||||
| Female | 56 (52.8) | 29 (54.7) | 16 (48.5) | 5 (55.6) | 6 (54.5) | 0.95 |
| Male | 50 (47.2) | 24 (45.3) | 17 (51.5) | 4 (44.4) | 5 (45.5) | |
| Site of primary tumor | ||||||
| Colon | 55 (51.9) | 28 (52.8) | 16 (48.5) | 5 (55.6) | 6 (54.5) | 0.97 |
| Rectum | 51 (48.1) | 25 (47.2) | 17 (51.5) | 4 (44.1) | 5 (45.5) | |
| Timing of hepatic metastases | ||||||
| Synchronous | 44( 41.5) | 19 (35.8) | 20 (60.6) | 2 (22.2) | 3 (27.3) | 0.05 |
| Metachronous | 62 (58.5) | 34 (64.2) | 13 (39.4) | 7 (77.8) | 8 (72.7) | |
| Surgery type | ||||||
| Minor (1-2 segment) | 81 (76.4) | 42 (79.2) | 24(72.7) | 9 (100) | 6 (54.5) | 0.10 |
| Major (≥ 3 segment or hemihepatectomy) | 25 (23.6) | 11 (20.8) | 9 (27.3) | 0 (0) | 5 (45.5) | |
| No. of hepatic CRM | ||||||
| Single | 61 (57.5) | 34 (64.2) | 17 (51.5) | 6 (66.7) | 4 (36.4) | 0.29 |
| Multiple | 45 (42.5) | 19 (35.8) | 16 (48.5) | 3 (33.3) | 7 (63.6) | |
| Largest hepatic CRM tumor size, cm | 10.4 | 4.87 | 4.55 | 4.73 | 4.05 | 0.87 |
| Median estimated blood loss, mL | 200 | 400 | 350 | 600 | 300 | 0.90 |
| Duration of chemotherapy, wk (median) | 4 | 0 | 4.8 | 4.1 | 0 | < 0.0001 |
| Postoperative complication | ||||||
| Yes | 20 (18.9) | 7 (13.2) | 9 (27.3) | 0 (0) | 4 (36.4) | 0.07 |
| No | 86 (81.1) | 46 (86.8) | 24 (72.7) | 9 (100) | 7 (63.6) |
CRM: Colorectal metastases; HAI: Hepatic artery infusion.